Overview

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy

Status:
Completed

Trial end date:
2020-11-04

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of brivaracetam (BRV) administered intravenously (iv) in subjects >= 1 month to < 16 years of age with epilepsy.

Phase:

Phase 2

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Treatments:

Brivaracetam